We read with interest the article entitled ''Presence of Diastolic Dysfunction in Patients with Peripheral Artery Disease'' by Yamasaki et al. 1 They 1 evaluated left ventricle (LV) function and measured plasma B-type natriuretic peptide (BNP) levels in patients with peripheral arterial disease (PAD). They reported a high prevalence of increased BNP levels and a strong independent association between the high BNP levels and the E/e 0 ratio, which reflects LV filling pressure. This highlights the presence of diastolic dysfunction in patients with PAD.
The ankle-brachial index (ABI) is a valuable diagnostic method for the detection of PAD. 2 Measurement of ABI in patients with subclinical PAD allows the timely initiation of preventive measures as well as detecting vascular disease in other arterial beds. Although the ABI is the method of choice for the primary diagnosis of PAD, other diagnostic tools should be considered when there is clinical suspicion of PAD. 3 Higher levels of N-terminal pro-BNP are independently associated with lower functional capacity in patients with PAD and may be a marker of hemodynamic stress in these patients according to the severity of PAD. 4 There is also evidence that quitting smoking, improving the lipid profile, lowering the blood pressure, and administering antiplatelet drugs reduce the risk of vascular events in these patients. 5 Statins not only lower the risk of vascular events but also improve the symptoms associated with PAD. 5 Furthermore, some medications such as antihypertensive treatment, aspirin, and statins may influence ABI parameters. 6, 7 Alcohol intake was also positively associated with body weight, high-density lipoprotein cholesterol levels, hypertension, coronary artery disease, and PAD. 8 Diastolic heart failure, which is also called heart failure with preserved ejection fraction (HF-PEF), is a syndrome in which patients have signs and symptoms of heart failure, normal or near normal LV ejection fraction (50%), and evidence of diastolic dysfunction. Recent epidemiological studies have demonstrated that more than half of all patients with heart failure have diastolic heart failure. 9 Patients with diastolic heart failure are a fairly heterogeneous group with complex pathophysiologic mechanisms. 10 According to the current guidelines, the diagnosis of HF-PEF requires 3 criteria such as signs or symptoms of heart failure, presence of a normal LV ejection fraction, and evidence of diastolic dysfunction. 11 Also, measurement of BNP should be considered to exclude other causes of dyspnea and obtain prognostic information. Elevated BNP levels may occur in many diseases associated with hypervolemia such as chronic renal failure, chronic liver disease, and hyperaldosteronism. 9 Also, respiratory diseases such as pulmonary embolism and chronic obstructive pulmonary disease may be associated with high level of BNP without left heart failure. 9 Important echocardiographic parameters for the assessment of diastolic function are atrial dimensions, myocardial mass, mitral inflow pattern, pulmonary vein flow, propagation velocity of mitral inflow, and tissue Doppler of the mitral annulus for classifying the patients according to the diastolic dysfunction (grades 1-4). 10 The most notable echocardiographic abnormalities seen in HF-PEF are an enlarged left atrium with hypertrophy, reduced left ventricular relaxation, and elevated filling pressures. 10 Triiodothyronine (T3) is inversely associated with markers of HF-PEF severity. Whether reduced T3 contributes to or is a consequence of increased severity of HF-PEF remains to be determined. 11 Finally, a low ABI has been demonstrated as a marker of decreased renal function over time in a general population, and the presence of renal dysfunction in patients with PAD is associated with higher morbidity and mortality rates as well as the occurrence of cardiovascular events. 12 In conclusion, a strong independent association between raised BNP levels and the E/e 0 ratio highlights the presence of diastolic dysfunction in patients with PAD. 1 However, the diagnosis of PAD and diagnostic methods might be affected by many factors. Large-scale prospective randomized clinical trials are needed to assess exact pathophysiological role of PAD.
